Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Double Dummy, Multicenter Study to Assess the Safety, Tolerability and Long-term Efficacy of Intravenous (10mg/kg) and Subcutaneous (300mg) Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Who Are Partial Responders to Secukinumab [EXTENSION OF 700203953]

Trial Profile

A Randomized, Double-blind, Double Dummy, Multicenter Study to Assess the Safety, Tolerability and Long-term Efficacy of Intravenous (10mg/kg) and Subcutaneous (300mg) Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Who Are Partial Responders to Secukinumab [EXTENSION OF 700203953]

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2019

At a glance

  • Drugs Secukinumab (Primary) ; Secukinumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms STATURE
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 17 Jun 2019 According to a Novartis media release, data from this trial were presented at the 24th World Congress of Dermatology 2019.
    • 12 May 2016 Results (pooled analysis of this and other nine studies, n = 3993) assessing safety of secukinumab published in the Journal of the American Academy of Dermatology.
    • 06 Oct 2013 Results were presented at the 22nd Congress of the European Association of Dermatology and Venereology (EADV), in October 2013, according to a Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top